Clinical data | |
---|---|
Other names | Xanamem; UE-2343; UE2343 |
Drug class | 11β-Hydroxysteroid dehydrogenase type 1 inhibitor |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
Chemical and physical data | |
Formula | C19H19N5O2S |
Molar mass | 381.45 g·mol−1 |
3D model (JSmol) | |
| |
|
Emestedastat (proposed brand name Xanamem; developmental code name UE-2343) is a steroidogenesis inhibitor which is under development for the treatment of major depressive disorder, Alzheimer's disease, and fragile X syndrome.[1][2] It specifically acts as a centrally penetrant inhibitor of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) and thereby inhibits the synthesis of the glucocorticoid steroid hormone cortisol.[1][3][4][2] As of August 2024, emestedastat is in phase 2 clinical trials for major depressive disorder and Alzheimer's disease and is in the preclinical stage of development for fragile X syndrome.[1][2] Clinical effectiveness for Alzheimer's disease has been mixed.[2] It was originated by the University of Edinburgh and is being developed by Actinogen Medical.[1]